Uncertainty in drug development: insights from a Portuguese firm
by Irina Saur-Amaral, Joaquim Jose Borges Gouveia
International Journal of Technology Intelligence and Planning (IJTIP), Vol. 3, No. 4, 2007

Abstract: Our study identified and analysed risks and uncertainties associated with the Drug Development Process (DDP) and managerial practices/methods to reduce them. Our approach was two-fold. First, we developed a theoretical model of risks/uncertainties and methods. Second, we performed an in-depth case study in a Portuguese firm to validate and enrich that model. We explain differences between theoretical and empirical insights and address key issues from the empirical study. Our final model has nine risk areas (divided in internal and external) and 15 methods (divided in outward and inward), and represents a significant instrument for further validation within pharmaceutical firms.

Online publication date: Sun, 16-Dec-2007

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Intelligence and Planning (IJTIP):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com